Lamivudine
- Generic Name
- Lamivudine
- Brand Names
- Cimduo, Combivir, Delstrigo, Dovato, Epivir, Epivir Hbv, Epzicom, Kivexa, Symfi, Triumeq, Trizivir, Zeffix, Lamivudine Teva Pharma B.V., Lamivudine Teva
- Drug Type
- Small Molecule
- Chemical Formula
- C8H11N3O3S
- CAS Number
- 134678-17-4
- Unique Ingredient Identifier
- 2T8Q726O95
- Background
A reverse transcriptase inhibitor and zalcitabine analog in which a sulfur atom replaces the 3' carbon of the pentose ring. It is used to treat Human Immunodeficiency Virus Type 1 (HIV-1) and hepatitis B (HBV).
- Indication
For the treatment of HIV infection and chronic hepatitis B (HBV).
- Associated Conditions
- Chronic Hepatitis B Infection, Human Immunodeficiency Virus (HIV) Infections, Human Immunodeficiency Virus Type 1 (HIV-1) Infection
- Associated Therapies
- -
The Incidence of Hepatitis B Reactivations in Patients Affected by Chronic Lymphocytic Leukemia With Ibrutinib
- First Posted Date
- 2018-05-18
- Last Posted Date
- 2022-05-12
- Target Recruit Count
- 109
- Registration Number
- NCT03528941
- Locations
- 🇮🇹
AOU Arcispedale S.Anna - UOC Ematologia e fisiopatologia della coagulazione, Cona, Ferrara, Italy
🇮🇹AOU Maggiore della Carità di Novara - SCDU Ematologia, Novara, Italy
🇮🇹AOU Città della Salute e della Scienza, Ospedale S.Giovanni Battista Molinette - SC Ematologia, Torino, Italy
Study With Dual Therapy Including Lamivudine (300 mg QD) Plus Raltegravir (1200 mg QD) in Virologically Suppressed HIV-1 Infected Patients Experiencing Inconvenience, Toxicity, Negative Impact on Co-morbidities or Risk of Drug-drug Interactions With Their Current Regimen
- Conditions
- Interventions
- First Posted Date
- 2017-11-06
- Last Posted Date
- 2018-07-31
- Lead Sponsor
- David Garcia Cinca
- Target Recruit Count
- 50
- Registration Number
- NCT03333083
- Locations
- 🇪🇸
Hospital Clínic i Provincial de Barcelona, Barcelona, Spain
Simplification Study of HIV-1 Infected Patients With Virological Suppression Under the Combination of Lamivudine (150 mg BID) Plus Raltegravir (400 mg BID) Switching to Lamivudine (300 mg QD) Plus Raltegravir (1200 mg QD) : Roll-over Study of the RALAM
- Conditions
- Interventions
- First Posted Date
- 2017-10-17
- Last Posted Date
- 2018-07-31
- Lead Sponsor
- David Garcia Cinca
- Target Recruit Count
- 49
- Registration Number
- NCT03311945
- Locations
- 🇪🇸
Hospital Clínic i Provincial de Barcelona, Barcelona, Spain
Islatravir (MK-8591) With Doravirine and Lamivudine in Participants Infected With Human Immunodeficiency Virus Type 1 (MK-8591-011)
- Conditions
- Interventions
- First Posted Date
- 2017-09-05
- Last Posted Date
- 2023-03-29
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 123
- Registration Number
- NCT03272347
- Locations
- 🇺🇸
North Texas Infectious Diseases Consultants, PA ( Site 0103), Dallas, Texas, United States
🇺🇸Whitman Walker Clinic ( Site 0108), Washington, District of Columbia, United States
🇺🇸Orlando Immunology Center (OIC) ( Site 0105), Orlando, Florida, United States
A Phase 2 Study of Lamivudine in Patients With p53 Mutant Metastatic Colorectal Cancer
- First Posted Date
- 2017-05-09
- Last Posted Date
- 2024-06-06
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 36
- Registration Number
- NCT03144804
- Locations
- 🇺🇸
Massachusetts general Hospital, Boston, Massachusetts, United States
Bioequivalence Study of Fixed Dose Versus Single Entities of Dolutegravir and Lamivudine
- First Posted Date
- 2017-03-13
- Last Posted Date
- 2019-02-21
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 154
- Registration Number
- NCT03078556
- Locations
- 🇺🇸
GSK Investigational Site, Overland Park, Kansas, United States
Dosing of Tenofovir and Efavirenz in Antiretroviral Therapy
- First Posted Date
- 2016-10-26
- Last Posted Date
- 2020-02-18
- Lead Sponsor
- Shanghai Public Health Clinical Center
- Target Recruit Count
- 184
- Registration Number
- NCT02945163
- Locations
- 🇨🇳
Shanghai Public Health Clinical Center, Shanghai, Shanghai, China
🇨🇳Yunnan provincial infectious disease hosipital, Kunming, Yunnan, China
🇨🇳The Second Hospital of Nanjing, Nanjing, Jiangsu, China
Optimization of Antiretroviral Therapy
- Conditions
- Interventions
- First Posted Date
- 2016-10-17
- Last Posted Date
- 2020-02-18
- Lead Sponsor
- Shanghai Public Health Clinical Center
- Target Recruit Count
- 184
- Registration Number
- NCT02935075
- Locations
- 🇨🇳
Yunnan AIDS care center, Kunming, Yunnan, China
🇨🇳The Second Hospital of Nanjing, Nanjing, Jiangsu, China
🇨🇳Shanghai Public Health Clinical Center, Shanghai, Shanghai, China
Renal Function Improvement in HBsAg Positive Kidney Transplantation Patients Under Telbivudine Treatment.
- Conditions
- Interventions
- First Posted Date
- 2016-09-09
- Last Posted Date
- 2016-09-09
- Lead Sponsor
- National Taiwan University Hospital
- Target Recruit Count
- 19
- Registration Number
- NCT02894554
Darunavir/Ritonavir + Lamivudine Versus Darunavir/Ritonavir +Emtricitabine/Tenofovir in Naïve HIV-1 Infected Subjects
- Conditions
- Interventions
- First Posted Date
- 2016-05-12
- Last Posted Date
- 2018-08-03
- Lead Sponsor
- Fundación Huésped
- Target Recruit Count
- 145
- Registration Number
- NCT02770508
- Locations
- 🇦🇷
Fundacion huesped, Caba, Buenos Aires, Argentina
🇦🇷Centro de Estudios Infectologicos SA (CTD Stamboulian), Caba, Buenos Aires, Argentina
🇦🇷Consultorio Infectológico Dr. Pryluka, Caba, Buenos Aires, Argentina
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.